GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
GENOPTIX INC. (GXDX) [hlAlert]

Rating:
Mkt Outperform
GXDX
down 33.68 %

GENOPTIX INC. (GXDX) rated Mkt Outperform with price target $28 by Avondale

Posted on: Tuesday,  Dec 14, 2010  11:25 AM ET by Avondale

Avondale rated Mkt Outperform GENOPTIX INC. (NASDAQ: GXDX) on 12/14/2010. Previously Avondale rated Mkt Outperform GENOPTIX INC. (NASDAQ: GXDX) on 12/22/2009.,
when the stock price was $37.70. Since then, GENOPTIX INC. has lost 33.69% as of 03/07/2011's recent price of $25.00.
If you would have followed the previous Avondale's recommendation on GXDX, you would have lost 33.68% of your investment in 440 days.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community- based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.

Avondale’s research analysts are charged with producing high quality, independent, value-added, and timely investment analysis / advice. The firm’s strategy is to deemphasize maintenance research, and instead direct the overwhelming majority of our efforts on developing well-constructed, actionable recommendations, in part by leveraging proprietary networks of industry contacts. Avondale’s growing research department now totals 25 professionals. Senior analysts average 14 years of industry experience and are routinely recognized by a variety of nationally known rating entities. In the last two years, Avondale Analysts were named to the Wall Street Journal’s Best on the Street poll as well as Forbes.com’s Top Analyst Rankings.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/14/2010 11:25 AM Buy
None
20.92 28.00
as of 12/31/2010
1 Week up  1.17 %
1 Month up  15.75 %
3 Months up  39.15 %
1 YTD down  -44.38 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/22/2009 2:25 PM Buy
None
37.70 43.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy